Compare Iris Energy Limited (IREN) vs Moderna, Inc. (MRNA) Price & Performance

IREN stock trades at $35.05, down 9.41% in 24 hours amid a bearish technical signal. The company is executing a pivot from Bitcoin mining to AI cloud services, with a $9.7 billion Microsoft deal, but faces ballooning losses and negative net margins. Analyst consensus remains bullish with an $81 price target, yet recent earnings misses and high valuations (P/E 51.42) highlight execution risks.

Outlook: Long-term growth potential from AI infrastructure demand is significant, but near-term profitability challenges and capital intensity pose risks. Investors should weigh strong analyst support against weak earnings trends and high cash burn from aggressive expansion plans.

Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.

Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.